{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"230"}],"units":"Participants"}],"description":"Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.","groups":[{"description":"Nivolumab 360 mg Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery; then post surgery nivolumab 480 mg Q4W adjuvant treatment for up to 13 cycles (approximately 1 year)","id":"OG000","title":"Nivolumab + SOC Chemotherapy"},{"description":"Placebo Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery, then post-surgery placebo Q4W for up to 13 cycles (approximately 1 year).","id":"OG001","title":"Placebo + SOC Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one dose of study medication in neoadjuvant or adjuvant setting.","reportingStatus":"POSTED","timeFrame":"From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)","title":"The Number of Participants With Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}